logo

PROF

Profound Medical·NASDAQ
--
--(--)
--
--(--)
1.12 / 10
Underperform

Fundamental metrics are concerning: Net income-to-revenue is negative, ROA and net profit margins are deeply negative, and key valuation ratios (Asset-MV, Revenue-MV, Cash-MV) rank in the weakest performance quartiles. Only the interest-coverage ratio and net-profit-to-total-profit show moderate strength, but they are insufficient to offset broader weaknesses. Overall, the company's fundamentals are rated underperform, signaling limited investment appeal.

Fundamental(1.12)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-1.64
Score2/3
Weight-0.30%
1M Return0.09%
ROA (%)
Value-61.13
Score0/3
Weight17.02%
1M Return-7.78%
Net profit attributable to parent company shareholders / Net profit (%)
Value100.00
Score2/3
Weight5.72%
1M Return-1.71%
Net income-Revenue
Value-0.17
Score1/3
Weight8.07%
1M Return-2.55%
Cash-UP
Value-0.06
Score2/3
Weight13.93%
1M Return-4.86%
Annualized net profit margin on total assets (%)
Value-81.50
Score0/3
Weight17.02%
1M Return-7.78%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight6.44%
1M Return-1.95%
Asset-MV
Value-0.50
Score0/3
Weight10.80%
1M Return-3.57%
Cash-MV
Value-0.07
Score1/3
Weight15.31%
1M Return-5.64%
Net profit / Total profit (%)
Value100.66
Score2/3
Weight6.00%
1M Return-1.71%
Is PROF undervalued or overvalued?
  • PROF scores 1.12/10 on fundamentals and holds a Premium valuation at present. Backed by its -74.32% ROE, -275.18% net margin, -5.73 P/E ratio, 7.33 P/B ratio, and 2.94% earnings growth, these metrics solidify its Underperform investment rating.